Bioverativ to Present at the Jefferies 2017 Healthcare Conference
Get Alerts BIVV Hot Sheet
Join SI Premium – FREE
WALTHAM, Mass.--(BUSINESS WIRE)-- Bioverativ Inc. (NASDAQ: BIVV) announced today that it will present at the Jefferies 2017 Healthcare Conference. The event will be webcast live on Tuesday, June 6, 2017 at 10:30 a.m. EDT. To access the live webcast, please visit Bioverativ’s Investors page at investors.bioverativ.com. An archived version of the webcast will be available following the presentation.
About BioverativBioverativ (NASDAQ: BIVV) is a global biotechnology company dedicated to transforming the lives of people with hemophilia and other rare blood disorders through world-class research, development and commercialization of innovative therapies. Launched in 2017 following separation from Biogen Inc., Bioverativ builds upon a strong heritage of scientific innovation and is committed to actively working with the blood disorders community. The company’s mission is to create progress for patients where they need it most and its hemophilia therapies when launched represented the first major advancements in hemophilia treatment in more than two decades. For more information, visit www.bioverativ.com or follow @bioverativ on Twitter.
View source version on businesswire.com: http://www.businesswire.com/news/home/20170605006255/en/
Bioverativ Inc.
INVESTOR CONTACT:
Susan Altschuller,
Ph.D., +1-781-663-4360
[email protected]
Source: Bioverativ Inc.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Lightweight Inflatable Rooftop Tent Portal Nomis One Debuts on Kickstarter
- Banco Comercial Português, S.A. informs about Interim report on the transactions conducted under the Share Buy- Back Programme
- Business For Good, LLC Introduces the Future of Business: People. Planet. Profit.
Create E-mail Alert Related Categories
Press ReleasesRelated Entities
Jefferies & Co, TwitterSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!



Tweet
Share